Safety and tolerability of continuous inhaled iloprost in critically ill pediatric pulmonary hypertension patients: A retrospective case series

Inhaled iloprost (iILO) has shown efficacy in treating patients with hypoxic lung disease and pulmonary hypertension, inducing selective pulmonary vasodilation and improvement in oxygenation. However, its short elimination half‐life of 20–30 min necessitates frequent intermittent dosing (6–9 times p...

Descripción completa

Detalles Bibliográficos
Autores principales: Colglazier, Elizabeth, Ng, Angelica J., Parker, Claire, Woolsey, David, Holmes, Raymond, Dsouza, Allison, Becerra, Jasmine, Stevens, Leah, Nawaytou, Hythem, Keller, Roberta L., Fineman, Jeffrey R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507570/
https://www.ncbi.nlm.nih.gov/pubmed/37731624
http://dx.doi.org/10.1002/pul2.12289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507570/
https://www.ncbi.nlm.nih.gov/pubmed/37731624
http://dx.doi.org/10.1002/pul2.12289

Ejemplares similares